Oxipit vs Qure AI
The furthest point on the autonomy axis against the broadest regulatory footprint. Oxipit holds the only approval anywhere for autonomous diagnostic reporting, certified in Europe to identify high confidence normal chest radiographs and issue finalised reports with no radiologist involved, and the regulatory bar forced it to publish operating characteristics most vendors never disclose. Qure triages and flags across nine products with the widest chest radiograph regulatory footprint in the market, and the radiologist reads every study. For a European service drowning in normal films, Oxipit removes them from the queue entirely, which nothing else can do. The condition is permanent: its false negative rate at the operating threshold has to be monitored locally forever, because nobody will ever catch the miss.
- It is the only regulatory approved application performing diagnostic reporting autonomously, holding certification to identify high confidence normal chest radiographs and issue finalised reports with no radiologist involved.
- The regulatory bar forced disclosure most vendors never face, and the company published the operating characteristics behind it.
- For a service whose backlog is normal chest films, removing them from the worklist entirely is a structural saving rather than an incremental one.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products with published device dossiers.
- It is deployed where reading capacity is thinnest, including public health screening programmes, which is a harder operating environment than a hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it.
Side by Side
| Axis | O Oxipit |
Q Qure AI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
This is the sharpest autonomy comparison in imaging and the evidence bars are not the same. An application that issues a finalised report needs its false negative rate at the operating threshold published and revalidated locally, because a missed finding on an autonomously reported film is seen by nobody, ever, while a triage product leaves the radiologist reading every study.
Oxipit's certification is European and does not transfer to other jurisdictions, and its acquisition raises questions about which entity holds the certification and the security posture. Neither publishes pricing.